comprehensive -WSS

comprehensive

author：hotspot 2025-09-29 20:17:23 - browse：89

Photo illustration of Covid 19 testing swabs on a blue background. — Timothy Stenzel led the FDA's diagnostics division during the Covid-19 pandemic, as the agency scrambled to push through and validate accurate Covid tests. Adobe

Timothy Stenzel, the federal regulator who led the Food and Drug Administration’s diagnostics division during the chaotic time of Covid-19 pandemic, has left the agency. The FDA confirmed Thursday that Stenzel, who led the FDA’s office of in vitro diagnostics, retired at the end of 2023.

During the early days of the pandemic, Stenzel was in the middle of a turf battle between the Centers for Disease Control and Prevention and the FDA over the regulation of Covid tests. At one point, the CDC made Stenzel wait at its facility overnight after he arrived for a meeting on Covid test development, Politico reported at the time.

It was a hectic time. Testmakers rapidly introduced new Covid-19 screening products with little data, as it was a brand new virus. The pandemic especially laid bare FDA’s inability to control lab-developed tests (LDTs). Many of the Covid-19 PCR tests fell in this category. Early on, using powers granted by the public health emergency, the FDA required labs to apply for emergency use authorization. But a STAT investigation found that the Department of Health and Human Services told the FDA to stop this measure, despite knowing that many of the tests may have been inaccurate.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Caitlin Bernard's story shows physicians can't shy from advocacy

WSS

Caitlin Bernard's story shows physicians can't shy from advocacy

Will.i.am, Britney Spears release new single, 'Mind Your Business'

Why an extreme heat and wildfire smoke combination can be so dangerous

FDA approves RSV monoclonal antibody for infants, toddlers

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Startup Neumora takes a novel depression drug to Phase 3

explore

comprehensive

entertainment

Heart attack and stroke risk calculators need revising

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

At least 13 dead in Texas as scorching temps continue

Death toll from an explosion and collapse of a Paris building in June climbs to 3

23andMe had bad news about my health. I wish a person had delivered it

Sanders adds drug shortage policies to pandemic preparedness bill

Walensky prepares to leave CDC — and Congress — behind

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Court strikes down limits on filming of police in Arizona

Wikipedia

AbbVie dramatically boosts its spending on lobbying

Sanofi seeks simpler, safer CRISPR sickle cell cure

Listen: Wegovy in the brain & pivotal Alzheimer's data

AI can’t replace a physician’s gut feeling

Marvel Studios reveals new trailer for 'The Marvels': Watch here

A public scorecard can help hold safety

focus

leisure time

entertainment

focus